खोज परिणाम - Lalezari, Jacob

परिणाम को परिष्कृत करें
  1. 1
    Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

    Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab द्वारा Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z.

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  2. 2
    Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

    Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy द्वारा Hatano, Hiroyu, Lampiris, Harry, Fransen, Signe, Gupta, Soumi, Huang, Wei, Hoh, Rebecca, Martin, Jeffrey N., Lalezari, Jacob, Bangsberg, David, Petropoulos, Christos, Deeks, Steven G.

    प्रकाशित 2010
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  3. 3
    Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

    Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects द्वारा Hanna, George J., Lalezari, Jacob, Hellinger, James A., Wohl, David A., Nettles, Richard, Persson, Anna, Krystal, Mark, Lin, Pinfang, Colonno, Richard, Grasela, Dennis M.

    प्रकाशित 2011
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  4. 4
    HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

    HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis द्वारा Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  5. 5
    540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis

    540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis द्वारा Brinson, Cynthia, Lalezari, Jacob, Latiff, Gulam H, Thompson, Melanie, Echevarría, Juan, Treviño-Pérez, Sandra, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  6. 6
    Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis

    Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis द्वारा Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  7. 7
    Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

    Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-s... द्वारा Einstein, Mark H, Takacs, Peter, Chatterjee, Archana, Sperling, Rhoda S, Chakhtoura, Nahida, Blatter, Mark M, Lalezari, Jacob, David, Marie-Pierre, Lin, Lan, Struyf, Frank, Dubin, Gary

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  8. 8
    1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis

    1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis द्वारा Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  9. 9
    Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

    Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with A... द्वारा Lalezari, Jacob P., Aberg, Judith A., Wang, Laurene H., Wire, Mary Beth, Miner, Richard, Snowden, Wendy, Talarico, Christine L., Shaw, Shuching, Jacobson, Mark A., Drew, W. Lawrence

    प्रकाशित 2002
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  10. 10
    Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

    Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection द्वारा Lalezari, Jacob, Asmuth, David, Casiró, Arnaldo, Vargas, Hugo, Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie, McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao-Jian, Sullivan-Bólyai, John, Mayers, Douglas

    प्रकाशित 2012
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  11. 11
    Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

    Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody द्वारा Jacobson, Jeffrey M., Thompson, Melanie A., Lalezari, Jacob P., Saag, Michael S., Zingman, Barry S., D’Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

    प्रकाशित 2010
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  12. 12
    Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

    Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults द्वारा Jacobson, Jeffrey M., Lalezari, Jacob P., Thompson, Melanie A., Fichtenbaum, Carl J., Saag, Michael S., Zingman, Barry S., D'Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

    प्रकाशित 2010
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  13. 13
    Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study द्वारा Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan

    प्रकाशित 2015
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  14. 14
    Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection

    Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection द्वारा Sulkowski, Mark S., Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F., Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M., Symonds, William T., Subramanian, G. Mani, McHutchison, John G., Rodriguez-Torres, Maribel, Dieterich, Douglas

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  15. 15
    Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Maraviroc for Previously Treated Patients with R5 HIV-1 Infection द्वारा Gulick, Roy M., Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B., McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W., van der Ryst, Elna, Mayer, Howard

    प्रकाशित 2008
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  16. 16
    Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

    Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab द्वारा Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  17. 17
    Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

    Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing द्वारा Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  18. 18
    Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial

    Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial द्वारा Gnann, John W., Crumpacker, Clyde S., Lalezari, Jacob P., Smith, Jean A., Tyring, Stephen K., Baum, Kenneth F., Borucki, Michael J., Joseph, W. Patrick, Mertz, Gregory J., Steigbigel, Roy T., Cloud, Gretchen A., Soong, Seng-jaw, Sherrill, Lanette C., DeHertogh, Deborah A., Whitley, Richard J., Group, the Collaborative Antiviral Study Group (Casg)/aids Clinical Trials Group (Actg) Herpes Zoster Study

    प्रकाशित 1998
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  19. 19
    All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

    All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study द्वारा Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A

    प्रकाशित 2015
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  20. 20
    Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study द्वारा Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor

    प्रकाशित 2013
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:

खोज साधन: